May 12, 2015
Astellas Pharma withdrew its new drug application (NDA) in Japan for nateglinide in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes and discontinued its development “for strategic reasons,” the company revealed at an earnings conference...read more